SB 030

Drug Profile

SB 030

Alternative Names: SB-030; SBCV 030

Latest Information Update: 28 Feb 2017

Price : $50

At a glance

  • Originator SYMIC Biomedical
  • Class Proteoglycans; Vascular disorder therapies
  • Mechanism of Action Inflammation mediator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Peripheral arterial disorders

Most Recent Events

  • 22 May 2017 Symic Bio plans the phase III trial for Peripheral arterial disorders (Prevention) in USA in 2018
  • 24 Feb 2017 Symic Biomedical completes enrolment in its phase I/II trial for Peripheral arterial disorders in Australia and New Zealand (Parenteral)
  • 27 Oct 2015 Phase-I/II clinical trials in Peripheral arterial disorders in Australia and New Zealand (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top